CLS: Immunophotonics announces status at clinicaltrials.gov for the intratumoral injection of IP-001, following thermal ablation, in patients with advanced solid tumors
LUND, SWEDEN October 19, 2020 - Clinical Laserthermia Systems AB (publ) (CLS) and Immunophotonics, Inc. have, as previously announced, a research collaboration under which a Phase 1b/2a clinical trial regarding cancer patients with certain solid tumor indications is carried out. The research will utilize each company’s respective products and methodologies during treatments and is intended to support early phase clinical trials facilitated by a leading clinical organization. The trial is now recruiting patients. The